Newsroom

Shawn Cuddy and his Band at the Brook - 11th September 2015

Events - Mon, 03/08/2015 - 16:00
Date:  Friday, 11 September 2015 - 7:00pm Shawn Cuddy and his Band at the Brook

An evening of great songs from this wonderful Irish crooner.

Cost: 

£16.50

Contact:  The Brook Box Office Telephone:  01353 721 748 or 01353 669 759 Email:  info@brookentertainment.co.uk Website:  The Brook Location The Brook 49 Brook Street Soham, Ely CB7 5AD United Kingdom See map: Google Maps

Chance to see International Space Station over East of England tonight

Newmarket Journal - Mon, 03/08/2015 - 15:31

The International Space Station (ISS) will glide across ​the East of England night skies ​this week​.

Categories: Local Press

China's slowdown threatens the euro zone core more than the fragile South

Reuters UK Business News - Mon, 03/08/2015 - 15:25
LONDON (Reuters) - Few parts of the world will remain unscathed by the plunging stock markets and economic slowdown rocking China, but the companies of Europe's soft underbelly may weather it best.








UK launches review of financial advice market

Reuters UK Business News - Mon, 03/08/2015 - 14:38
LONDON (Reuters) - Britain has launched a review into the way consumers access financial advice amid concerns of an "advice gap" following recent changes to the pensions and savings industry.








Hiding HIV virus 'flushed out' by skin cancer drug

NHS Choices - Behind the Headlines - Mon, 03/08/2015 - 14:30

"HIV flushed out by cancer drug", BBC News reports. This headline was prompted by laboratory research showing the promising results of a cancer drug being used to treat HIV.

In the early stages of HIV infection, some of the virus effectively goes into hiding in so-called HIV "reservoirs". These viruses are not "active", so standard anti-HIV drug treatments do not kill them.

In this study, researchers found viruses in blood samples from people with HIV infection could be reactivated using a cancer drug. They believe this would mean the viruses could then be identified by standard drug treatments, and killed. The drug did not appear to be toxic to other blood cells, although it wasn't tested on living humans.

While these are promising results, the experiments are at an early stage and it is not known if it would be safe to use the drug in this way for people infected with HIV.

The drug is currently used on the skin to treat a condition called actinic keratoses, which makes it unclear what effects the drug would have if used internally.  

Where did the story come from?

The study was carried out by researchers from the University of California, the San Francisco Veterans Affairs Medical Center, and Williams College, all in the US.

It was jointly funded by the National Institute of Health, UC Davis Research Investments in Science and Engineering (RISE), the Brazilian Federal Agency, and the Swiss National Science Foundation. Researchers say the funding organisations had no role in the study design, data collection and analysis.

The study was published in the peer-reviewed medical journal PLoS Pathogens.

In general, the media reported the story accurately, but the study's limitations were not fully explained.

The BBC reported an interesting quote from one of the researchers, Dr Satya Dandekar, who said: "We are excited to have identified an outstanding candidate for HIV reactivation and eradication that is already approved and is being used in patients. This molecule has great potential to advance into translational and clinical studies."

But although the drug is being used on patients, it is currently just applied to the skin. The effects may be very different if the whole body is exposed to the drug, as would be required to locate hidden reservoirs of HIV. 

What kind of research was this?

This laboratory study aimed to assess whether a drug currently used to treat a skin condition could be used to reactivate the HIV virus.

Currently available forms of anti-retroviral therapy (ART) are effective in stopping HIV replication, but they do not eliminate "latent" reservoirs of the virus in people infected with HIV. Other studies suggest starting ART early may not prevent latent virus reservoirs forming, or eliminate them.

More recent studies have looked at how some compounds may disrupt the cell signalling pathways that allow HIV to become latent in someone infected with the virus.

Researchers say some of these compounds effectively induce latent HIV reactivation in laboratory settings. One of these compounds is ingenol-3-angelate (PEP005), which is currently approved for clinical use and is used to treat a skin condition called actinic keratoses. This can develop into skin cancer if left untreated.

In this type of study, using cells in a lab, treatments sometimes show positive results, but don't always prove effective in living humans. 

What did the research involve?

The research included a cell culture of latent HIV with "defective" genes. Researchers say this clone is widely used for HIV latency studies.

The researchers collected blood samples from 13 people who were infected with HIV and receiving ART – 12 of these had been on ART for more than three years.

All the individuals had had "suppressed" viral activity for more than six months. The researchers also collected cells from uninfected individuals to act as a control.

All the human and cultured cells were incubated, with compounds being tested for 24 or 72 hours to see whether the cells were dead or alive after the tests.

To determine the potential of PEP005, cells were treated with increasing concentrations of PEP005. 

What were the basic results?

PEP005 increased the reactivation of the cell culture of latent HIV. The effect was even greater when PEP005 was combined with other compounds that also activate latent HIV.

When PEP005 was tested on blood samples from people with HIV infection, it activated latent HIV-infected cells in most of the samples. Again, the effects were higher when PEP005 was used in combination with other compounds.

Researchers also assessed potential side effects of PEP005 and found no significant toxicity or side effects on other blood cells from these samples. 

How did the researchers interpret the results?

Researchers concluded that PEP005 "effectively reactivated HIV from latency in primary CD4+ T cells from HIV-infected individuals receiving ART", and a combination of this and another compound increased this reactivation. They say these results "represent a new group of lead compounds for combating HIV latency". 

Conclusion

This laboratory study found the cancer drug PEP005 may be able to activate latent HIV. This could mean conventional anti-HIV treatments should then be able to eradicate it.

The drug has so far only shown positive results in the laboratory setting and has not been tested on humans in this way. As such, it's too early to tell if this really will help people infected with HIV to be free of the virus for good.

While these are some positive results, the side effects of this drug in humans has not been fully explored.

There is currently no cure for HIV, but there are treatments that can delay the start of symptoms. The World Health Organization (WHO) reports there are 35 million people currently living with HIV globally. Even if effective treatments were available, it's wise to practice safer sex using barrier contraception.

Links To The Headlines

HIV flushed out by cancer drug. BBC News, July 31 2015

Scientists discover how to flush HIV out of a patient's body, raising hopes they can eradicate the disease. Daily Mail, July 31 2015

Links To Science

Jiang G, et al. Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. PLoS Pathogens. Published July 30 2015

Categories: NHS Choices

IMF says Western sanctions could cut 9 percent off Russia's GDP

Reuters UK Business News - Mon, 03/08/2015 - 14:02
MOSCOW (Reuters) - Sanctions linked to the Ukraine crisis could end up costing Russia 9 percent of its gross domestic product, the International Monetary Fund said on Monday.








Police launch gem of an appeal for jewellery box donations in Ely and Fenland

Ely Standard - Mon, 03/08/2015 - 13:47

An appeal for empty jewellery boxes has captured the imagination of hundreds of people in Ely and Fenland prompting donations by the dozen.

Categories: Local Press

‘Laughing’ occupants of orange Clio - or possibly a Corsa- flee the scene of A142 in which motorcyclist and passenger injured

Ely Standard - Mon, 03/08/2015 - 13:35

An appeal has begun to find the occupants of an orange Clio – or possibly a Corsa- who sped off from the scene of an accident involving a motorcyclist and his passenger.

Categories: Local Press

MP drops in on a voluntary service that can help those on low incomes furnish their homes

Ely Standard - Mon, 03/08/2015 - 13:27

Lucy Frazer, MP for South East Cambridgeshire, is encouraging people to support and make use of local service Cambridge Re-Use.

Categories: Local Press

Shire buys U.S. company to access experimental pink eye treatment

Reuters UK Business News - Mon, 03/08/2015 - 13:26
(Reuters) - Pharmaceutical company Shire Plc said it had bought New York-based Foresight Biotherapeutics Inc for $300 million in cash, gaining access to a late-stage therapy being developed for the treatment of pink eye.








Arsonists cause fires at Isleham and Soham - police appeal for information

Ely Standard - Mon, 03/08/2015 - 12:35

Four blazes have been tackled by fire crew in the last two days, two of which were started by arsonists.

Categories: Local Press

Flat-rate equals ‘two classes of pensioners’ claims Soham man

Ely Standard - Mon, 03/08/2015 - 12:27

New state pension plans that come into force next April will create two classes of pensioners.

Categories: Local Press

Traffic held up as trailer over turns on the outskirts of Ely - luckily no one was injured

Ely Standard - Mon, 03/08/2015 - 12:13

A trailer has overturned on one of Ely’s busiest junctions today.

Categories: Local Press

Rolls-Royce shares rise as activist stake fuels turnaround talk

Reuters UK Business News - Mon, 03/08/2015 - 11:55
LONDON (Reuters) - Shares in British engineering company Rolls-Royce , under pressure after a run of profit warnings, rose for a second session on Monday on speculation it could speed up turnaround plans after an activist investor became its biggest shareholder.








Woman in her 20s taken to hospital after being hit by a reversing car in Wisbech

Ely Standard - Mon, 03/08/2015 - 11:50

A woman was taken to hospital after being hit by a reversing car in Wisbech.

Categories: Local Press

Man in his 70s makes emergency landing in light aircraft at Benwick- air ambulance called out

Ely Standard - Mon, 03/08/2015 - 11:45

A man in his seventies made an emergency landing in his light aircraft on a grass airfield near March yesterday.

Categories: Local Press

German carmakers buy Nokia maps to fend off digital rivals

Reuters UK Business News - Mon, 03/08/2015 - 11:42
FRANKFURT (Reuters) - German carmakers BMW , Audi and Mercedes , will pay around 2.5 billion euros (1.80 billion pounds) to buy Nokia's maps business, beating out high-tech rivals for location services seen as key to the future of self-driving cars.








Serial drink driver banned after fourth offence

Newmarket Journal - Mon, 03/08/2015 - 11:37

A serial drink-driver has been banned for three years for his fourth offence - but escaped prison with a suspended sentence.

Categories: Local Press

Thales wins one billion euro contract to upgrade London underground lines

Reuters UK Business News - Mon, 03/08/2015 - 11:29
PARIS (Reuters) - French transport and defence group Thales has won a contract worth one billion euros (760 million pounds) to upgrade four London Underground lines, including the oldest part of the network.








Chinese factories face headwinds in July, Europe withstands Greek turmoil

Reuters UK Business News - Mon, 03/08/2015 - 11:13
LONDON/SYDNEY (Reuters) - Economic headwinds facing Chinese manufacturers intensified last month, with conditions deteriorating to their weakest level in two years, while euro zone factories largely shrugged off Greece's brush with bankruptcy.








Pages